Skip to content
PoliticalRepoPoliticalRepo

Subjects · United States

Healthcare

Records whose title is actually about this topic. Use a country filter if the list is still too broad.

1,351 records in US in 2023

All countriesUnited States · 38,233Austria · 12,334Ireland · 11,065France · 6,170Netherlands · 4,601Germany · 1,173United Kingdom · 1,138European Union · 715Belgium · 4Search this topic

Records

Bill· HRH.R. 2001 (118th)referred

To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health Innovation Account, CURES Act for fiscal year 2024.

United States · United States Congress · 29 March 2023

This bill limits FY2024 funding for the National Institutes of Health for the CURES Act Innovation Account. (This account provides multiyear funding for specific scientific initiatives, including the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative and the Cancer Moonshot.)

Bill· HRH.R. 1970 (118th)referred

To provide for a limitation on availability of funds for Department of Health and Human Services, Centers for Disease Control and Prevention Energy Employees Occupational Illness Compensation Program for fiscal year 2024.

United States · United States Congress · 29 March 2023

This bill limits FY2024 funding for the Centers for Disease Control and Prevention for the Energy Employees Occupational Illness Compensation Program. (This program provides cash benefits and medical coverage to certain civilians who worked in the development and testing of nuclear weapons.)

Bill· HRH.R. 2377 (118th)referred

Saving Access to Laboratory Services Act

United States · United States Congress · 29 March 2023

Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.

Law· HRH.R. 2365 (118th)enacted

Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act

United States · United States Congress · 29 March 2023

National Plan to End Parkinson's Act This bill requires the Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease (a progressive brain disorder that causes unintended or uncontrollable movements) and related conditions. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent, slow the progression of, and cure the disease; and (2) improve diagnosis, treatment, and care of those with the disease. HHS must also annually assess the preparations for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and treatment of Parkinson's disease. The provisions of the bill terminate at the end of calendar year 2035.

Bill· SS. 1067 (118th)open

Ensuring Timely Access to Generics Act of 2023

United States · United States Congress · 29 March 2023

Ensuring Timely Access to Generics Act of 2023 This bill establishes additional requirements related to citizen petitions concerning applications for generic drug or biosimilar market approval. ( Citizen petitions are petitions submitted by third parties requesting that the Food and Drug Administration (FDA) take certain actions, such as requiring additional warnings on a drug.) Under the bill, the FDA may deny a citizen petition that (1) was submitted primarily to delay the approval of the relevant application, or (2) does not on its face raise valid scientific or regulatory issues. Currently, the FDA may deny a petition as an attempt at delay only if the petition meets both of these requirements. The bill also requires the FDA to establish procedures for referring such a petition to the Federal Trade Commission. The bill also expressly requires a third party, before filing a lawsuit to force the FDA to set aside or prevent market approval of a generic drug or biosimilar, to first file a citizen petition with the information and arguments that form the basis of the lawsuit. A citizen petition must be filed within 60 days of when the filer knew or reasonably should have known the information that forms the basis of the petition.

Bill· HRH.R. 2376 (118th)referred

To amend the Indian Health Care Improvement Act and title 5 of the United States Code to facilitate participation in Federal benefits programs, and for other purposes.

United States · United States Congress · 29 March 2023

This bill expands eligibility for enrollment in the Federal Employees Health Benefits (FEHB) Program to employees of tribal colleges and universities. Specifically, the bill makes tribal colleges and universities eligible to purchase coverage, rights, and benefits under the FEHB program for their employees. The following tribal employers are currently entitled to purchase coverage, rights, and benefits under the program for their employees: (1) an Indian tribe or tribal organization carrying out programs under the Indian Self-Determination and Education Assistance Act, and (2) an urban Indian organization carrying out programs under the Indian Health Care Improvement Act.

Bill· HRH.R. 2369 (118th)referred

VALID Act of 2023

United States · United States Congress · 29 March 2023

Verifying Accurate Leading-edge IVCT Development Act of 2023 or the VALID Act of 2023 This bill requires the Food and Drug Administration (FDA) to regulate in vitro clinical tests (IVCTs). Currently, the FDA and the Centers for Medicare & Medicaid Services have authority to regulate in vitro diagnostic devices. The bill defines IVCTs, which includes in vitro diagnostic devices, as tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body to provide information about a disease, condition, or treatment. An IVCT may not be introduced into interstate commerce unless it has received FDA premarket approval or is covered by certain exemptions, such as an exemption for a test that (1) was developed and introduced before this bill's enactment and meets certain requirements, (2) is a low-risk test, (3) is solely for public health surveillance, (4) is covered by a technology certification issued under this bill, or (5) has received a humanitarian exemption or emergency use authorization. The FDA may grant upon application a technology certification. Generally, such a certification covers a group of tests that use a single technology and may be evaluated using a representative test. While such a certification is valid, a qualifying IVCT that falls within the scope of the certification shall be cleared for interstate commerce. The bill also imposes various requirements related to IVCTs, including those related to quality control, labeling, and reporting adverse events. The FDA shall have various enforcement authority, including authority to order the recall of an IVCT with a reasonable probability of causing serious adverse health consequences.

Bill· HRH.R. 2390 (118th)referred

Gun Violence Prevention Research Act of 2023

United States · United States Congress · 29 March 2023

Gun Violence Prevention Research Act of 2023 This bill authorizes the Centers for Disease Control and Prevention to conduct or support research on firearms safety or gun violence prevention.

Bill· HRH.R. 2389 (118th)referred

Resident Physician Shortage Reduction Act of 2023

United States · United States Congress · 29 March 2023

Resident Physician Shortage Reduction Act of 2023 This bill increases the number of residency positions eligible for graduate medical education payments under Medicare for qualifying hospitals, including hospitals in rural areas and health professional shortage areas. Current law provides for an increase of up to 200 positions per fiscal year beginning in FY2023, with a total increase of 1,000 positions; each hospital may receive up to 25 additional positions. Current law also provides for an additional increase of up to 200 positions for FY2026, with at least 100 of these positions for psychiatry or related specialties; each hospital may receive up to 10 additional positions. The bill provides for an additional increase of 2,000 positions per fiscal year from FY2025-FY2031; during this period, each hospital may receive up to 75 additional positions in total under the bill and current law. Additionally, one-third of the positions that are made available under the bill must be allocated to hospitals that are already operating above applicable resident limits. The bill also requires the Government Accountability Office to report on strategies to increase the diversity of the health professional workforce, including with respect to representation from rural, low-income, and minority communities.

Bill· SS. 1063 (118th)referred

Jobs and Opportunities for Medicaid Act

United States · United States Congress · 29 March 2023

Jobs and Opportunities for Medicaid Act This bill establishes work requirements under Medicaid for able-bodied adults. Specifically, the bill requires individuals who are between the ages of 18 and 65 and who are not otherwise unable to work due to a medical condition, family situation, or other listed reason to work or volunteer at least 20 hours per week, based on a monthly average, in order to qualify for Medicaid.

Bill· SS. 1062 (118th)referred

Jobs and Opportunities for SNAP Act of 2023

United States · United States Congress · 29 March 2023

Jobs and Opportunities for SNAP Act of 2023 This bill expands applicability of the work requirements for Supplemental Nutrition Assistance Program (SNAP) recipients who are able-bodied adults without dependents (ABAWDs). (SNAP recipients who are ABAWDs have work-related requirements in addition to the general SNAP work registration and employment and training requirements.) Specifically, this bill applies the work requirements for ABAWDs to adults who are not over 65 years old, whereas these requirements currently apply to adults who are not over 50 years old. Further, the ABAWD exemption for a parent or household member with responsibility for a dependent child is restricted to a dependent child under the age of seven. Currently, the child must be under the age of 18. The bill repeals COVID-19 public health emergency waivers issued for ABAWD work requirements. The bill also repeals an ABAWD waiver program that allows state exemptions based on an area (1) having an unemployment rate of over 10%, or (2) not having a sufficient number of jobs. Under current law, a state agency may exempt up to 12% of SNAP recipients from the ABAWD work requirements for each fiscal year; unused exemptions may be carried over and used in a subsequent fiscal year. The bill reduces the percentage of exemptions a state agency may provide to up to 3% of SNAP recipients, and unused exemptions may not be carried over.

Bill· SS. 1026 (118th)referred

Gun Violence Prevention Research Act of 2023

United States · United States Congress · 29 March 2023

Gun Violence Prevention Research Act of 2023 This bill authorizes the Centers for Disease Control and Prevention to conduct or support research on firearms safety or gun violence prevention.

Bill· SS. 1028 (118th)referred

Servicemembers and Veterans Empowerment and Support Act of 2023

United States · United States Congress · 29 March 2023

Servicemembers and Veterans Empowerment and Support Act of 2023 This bill modifies and implements policies and procedures related to Department of Veterans Affairs (VA) health care and benefits for veterans who have experienced military sexual trauma (MST), which is generally defined as physical assault of a sexual nature, battery of a sexual nature, or sexual harassment that occurred while the veteran was serving in the military. In the case of any veteran who claims that a covered mental health condition (e.g., post-traumatic stress disorder) based on MST was incurred or aggravated by active service, the VA must consider (1) a diagnosis of the condition by a mental health professional, (2) a medically proven link between current symptoms and MST, and (3) credible supporting evidence that MST occurred. The VA may not deny a veteran's claim of compensation for a covered mental health condition based on MST without first (1) advising the veteran that nonmilitary evidence and behavioral evidence may constitute credible corroborating evidence, and (2) allowing the veteran an opportunity to furnish the corroborating evidence or advise the VA of potential sources of such evidence. The Veterans Benefits Administration must conduct an annual special focus review on the accuracy of the processing of claims for disability compensation for disabilities relating to MST. Additionally, the bill (1) expands access to mental health care at VA facilities for survivors of MST, and (2) requires the Government Accountability Office to report on access to such care for MST survivors.

Bill· SS. 1038 (118th)referred

Drug Price Transparency in Medicaid Act of 2023

United States · United States Congress · 29 March 2023

Drug Price Transparency in Medicaid Act of 2023 This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.

Bill· SS. 1031 (118th)referred

EACH Act of 2023

United States · United States Congress · 29 March 2023

Equal Access to Abortion Coverage in Health Insurance Act of 2023 or the EACH Act of 202 3 This bill requires federal health care programs (e.g., Medicaid, Medicare, and the Children's Health Insurance Program (CHIP)) to provide coverage for abortion services and requires federal facilities to provide access to those services. Currently, coverage for such services under federal programs is generally only available in the case of rape, incest, or life endangerment. Additionally, the bill repeals certain provisions of the Patient Protection and Affordable Care Act that permit states to prohibit coverage of abortion services in plans offered through a health insurance exchange in the state. The bill also permits qualified health plans to use funds attributable to premium tax credits and reduced cost sharing assistance to pay for abortion services. The bill is not subject to the Religious Freedom Restoration Act of 1993, which generally prohibits the federal government from substantially burdening a person's exercise of religion even if the burden results from a generally applicable law.

Bill· SS. 1064 (118th)referred

National Plan to End Parkinson’s Act

United States · United States Congress · 29 March 2023

National Plan to End Parkinson's Act This bill requires the Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease (a progressive brain disorder that causes unintended or uncontrollable movements) and related conditions. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent, slow the progression of, and cure the disease; and (2) improve diagnosis, treatment, and care of those with the disease. HHS must also annually assess the preparations for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and treatment of Parkinson's disease. The provisions of the bill terminate at the end of calendar year 2035.

Bill· HRH.R. 1825 (118th)referred

Right to Try Clarification Act

United States · United States Congress · 28 March 2023

Right to Try Clarification Act This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances). The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.

PreviousPage 27 of 28Next